Halozyme 2025 revenue up 38%, Q4 EPS misses estimates

Halozyme Therapeutics

17/02/2026 21:09

Overview

Biopharmaceutical firm's 2025 revenue rose 38% to $1.4 bln, driven by ENHANZE growth

Q4 adjusted EPS missed analyst expectations

Company completed acquisitions of Elektrofi and Surf Bio, expanding technology portfolio

Outlook

Halozyme reiterates 2026 revenue guidance of $1.710 bln to $1.810 bln

Company expects 2026 royalty revenue of $1.130 bln to $1.170 bln

Halozyme projects 2026 adjusted EBITDA of $1.125 bln to $1.205 bln

Result Drivers

ENHANZE PRODUCTS - Royalty revenue grew 52% in 2025, driven by ENHANZE-enabled products like DARZALEX SC, Phesgo, and VYVGART Hytrulo

TECHNOLOGY ACQUISITIONS - Acquisitions of Elektrofi and Surf Bio expanded drug delivery technology portfolio, enhancing long-term royalty opportunities

NEW COLLABORATIONS - Entered new agreements with Takeda, Merus, and Skye Bioscience, and gained a new target nomination from Roche

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Miss
-$0.24
$2.20 (5 Analysts)
Q4 EPS
-$1.20
Q4 Net Income
-$141.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Halozyme Therapeutics Inc is $77.00, about 3.1% below its February 13 closing price of $79.44

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nPn8fLTDLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)